Abstract
Cancer detection at early stages expands therapeutic options and improves treatment efficacy. Existing cancer screening methods, however, are often invasive and have limited accuracy, subjecting patients to unnecessary follow-up procedures. Detection of plasma circulating tumor DNA (ctDNA) is a reliable method for detecting cancer, but sensitivity can be limited. Methylation signatures in cell-free DNA (cfDNA) can enhance cancer detection by providing cancer-specific epigenetic information. In addition, cfDNA from tumor cells are relatively shorter than cfDNA from normal cells, and this difference can be measured as a tumor-specific signal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
